400 related articles for article (PubMed ID: 31468288)
21. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
22. Overview of current and future systemic therapy for metastatic renal cell carcinoma.
Osawa T; Takeuchi A; Kojima T; Shinohara N; Eto M; Nishiyama H
Jpn J Clin Oncol; 2019 May; 49(5):395-403. PubMed ID: 30722031
[TBL] [Abstract][Full Text] [Related]
23. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
24. [Immunotherapy for renal cell carcinoma - current status].
Grimm MO; Foller S
Aktuelle Urol; 2018 Apr; 49(2):187-191. PubMed ID: 29587324
[TBL] [Abstract][Full Text] [Related]
25. Changes in Treatment Reality and Survival of Patients With Advanced Clear Cell Renal Cell Carcinoma - Analyses From the German Clinical RCC-Registry.
Goebell PJ; Staehler M; Müller L; Nusch A; Scheffler M; Sauer A; von Verschuer U; Tech S; Kruggel L; Jänicke M; Marschner N;
Clin Genitourin Cancer; 2018 Dec; 16(6):e1101-e1115. PubMed ID: 30061035
[TBL] [Abstract][Full Text] [Related]
26. [The present state and the future perspective of immunotherapy of renal cell carcinoma].
Kawashima H
Nihon Rinsho; 2015 Jan; 73(1):167-74. PubMed ID: 25626324
[TBL] [Abstract][Full Text] [Related]
27. The current role of immunotherapy for renal cell carcinoma in the era of targeted therapeutics.
Wong MK
Curr Oncol Rep; 2008 May; 10(3):259-63. PubMed ID: 18765157
[TBL] [Abstract][Full Text] [Related]
28. [Not Available].
Mery B; Jones S; Vallard A; Rowinski E; Guillot A; Magné N
Bull Cancer; 2018 Dec; 105 Suppl 3():S235-S241. PubMed ID: 30595152
[TBL] [Abstract][Full Text] [Related]
29. [Immunotherapy in renal cell carcinoma: A booming clinical research].
Baize N; Bigot P
Prog Urol; 2018 Mar; 28(3):137-145. PubMed ID: 29339141
[TBL] [Abstract][Full Text] [Related]
30. Update on targeted therapies for clear cell renal cell carcinoma.
Singer EA; Gupta GN; Srinivasan R
Curr Opin Oncol; 2011 May; 23(3):283-9. PubMed ID: 21330923
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy for metastatic renal cell carcinoma: A systematic review.
Peinemann F; Unverzagt S; Hadjinicolaou AV; Moldenhauer I
J Evid Based Med; 2019 Nov; 12(4):253-262. PubMed ID: 31430052
[TBL] [Abstract][Full Text] [Related]
32. Combination systemic therapy for advanced renal cell carcinoma.
Miller RE; Larkin JM
Oncologist; 2009 Dec; 14(12):1218-24. PubMed ID: 19939892
[TBL] [Abstract][Full Text] [Related]
33. Emerging immunotherapy in advanced renal cell carcinoma.
Mendiratta P; Rini BI; Ornstein MC
Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
[TBL] [Abstract][Full Text] [Related]
34. Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma.
Jang A; Lichterman JN; Zhong JY; Shoag JE; Garcia JA; Zhang T; Barata PC
Hum Vaccin Immunother; 2023 Dec; 19(3):2276629. PubMed ID: 37947202
[TBL] [Abstract][Full Text] [Related]
35. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
36. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
37. The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.
Ornstein MC; Rini BI
Expert Rev Anticancer Ther; 2016 Jun; 16(6):577-84. PubMed ID: 27144724
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
40. Complete and Prolonged Response of Renal Cell Carcinoma With Rhabdoid Features to Checkpoint Inhibitor Therapy.
Wynja E; Solomon B; Bleeker J
J Immunother; 2018 Sep; 41(7):340-342. PubMed ID: 29965859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]